MENLO PARK, Calif.–(BUSINESS WIRE)– #SeriesA–Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
Author: Business Wire
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics provides update on AZR-MD-001 Phase 2 clinical program targeting Meibomian Gland Dysfunction.
Global Retinal Surgery Devices Market Analysis Report 2022-2027: Major Company Profiles, Deals, Strategies, Growth Drivers and Recent Developments – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments – Forecast to 2027” report has been added to Re…
RetinAI Expands Operations with a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies
BERN, Switzerland & BOSTON–(BUSINESS WIRE)– #AI–RetinAI Medical AG (“RetinAI”), is a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, …
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that i…
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been do…
“3D print x craftsmanship” Achieved 200% in three days since eyewear brand "HYPHEN" has started crowdfunding by using KICKSTARTER
TOKYO–(BUSINESS WIRE)–New brand “HYPHEN”, researching and developing new structure of eyewear, by HYPHEN LTD. announced the spring 2023 model 2 series developed with the theme of luxury sports on the crowdfunding site KICKSTARTER. In three days from …
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
NASHVILLE, Tenn. & MENDRISIO, Switzerland–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S…
Versant Health Names Darrin Furtado Vice President of Underwriting
BALTIMORE–(BUSINESS WIRE)– #NewHire–VP of Underwriting Darrin Furtado brings over two decades of experience in finance and vision insurance to Versant Health
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
PARSIPPANY, N.J.–(BUSINESS WIRE)–Iveric Bio will present top-line efficacy and safety results from GATHER2, the Company’s second Phase 3 clinical trial of Zimura, at AAO 2022.
EyeCare Partners Launches New Innovation Center
ST. LOUIS–(BUSINESS WIRE)–EyeCare Partners launches new Innovation Center.
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
BOSTON–(BUSINESS WIRE)–Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing P…
Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD
BEDFORD, Mass–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today an…
Vietnam Eye Care Market Report 2022: Rising Incidences of Eye Infections and Diseases Driving Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vietnam Eye Care Market, By Product Type (Eyeglasses, Contact Lens, Intraocular Lens, Eye Drops, Eye Vitamins, Others), By Coating (Anti-Glare, UV, Others), By Lens Material, By Distribution Channel, By Region, Competition…
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
EMERYVILLE, Calif. & UBE, Japan–(BUSINESS WIRE)–Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag…
United States $40+ Billion Eyewear Markets, Competition Forecast & Opportunities, 2027F – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “United States Eyewear Market, By Product Type, By End User, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027F” report has been added to ResearchAndMarkets.com’s offering. United States eye…
Children's Hospital Los Angeles Identifies Molecular Markers to Increase Precision in Treatment of Retinoblastoma
LOS ANGELES–(BUSINESS WIRE)–Children’s Hospital Los Angeles Identifies Molecular Markers to Increase Precision in Treatment of Retinoblastoma
Optical Devices for Monitoring Patient Glucose Levels – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Devices for Monitoring Patient Glucose Levels” report has been added to ResearchAndMarkets.com’s offering. Noninvasive monitors that can measure analyte levels accurately and reliably have the capability to improve…
NovaBay Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that management will pres…
Global Macular Degeneration Treatment Market to 2028 – Featuring Bayer, Pfizer, Novartis and Aerie Pharmaceutical Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Macular Degeneration Treatment Market, By Type, By Stage Of Disease, By Route Of Administration, By Sales Channel, and By Geography – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028” report has been added to Re…